BOTHELL, Wash., Dec. 8 BioLife Solutions, Inc.(OTC Bulletin Board: BLFS), a leading developer and marketer of proprietarycGMP hypothermic storage and cryopreservation media products for cells,tissues, and organs, today announced that it has been granted a Europeanpatent for an application that includes claims related to protecting cellsfrom injury and death caused by cold temperatures used in biopreservation. Thepatent titled, "Inclusion of Apoptotic Regulators in Solutions for CellStorage at Low Temperature," was previously granted US patent protection.
Mike Rice, BioLife's chairman and CEO, noted that the new patent expandsthe protections of the Company's key intellectual property related toregulating the biologic process of apoptosis (programmed cell death) inresponse to the accumulated stress due to exposure to hypothermic and freezingtemperatures. The new patent is a direct result of BioLife's ongoing effort toincrease the value of its intellectual property portfolio and enableadditional product and licensing revenue streams for BioLife, he added.
"We've repeatedly shown via numerous internal and customer validationsthat our products better protect cells and tissues from the harmful necroticand apoptotic effects of hypothermic storage, freezing, and thawing, and as aresult, can extend the shelf life and improve the post preservation recovery,viability, and functional yield of both biologic source material as well asisolated cells," Rice said, adding that the Company has submitted severaladditional patent applications during 2008.
About BioLife Solutions, Inc.:
BioLife Solutions develops and markets patented hypothermicstorage/transport and cryopreservation media products for cells, tissues, andorgans. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platformof biopreservation media products are marketed to academic researchinstitutions, hospitals, and commercial companies involved in cell therapy,tissue engineering, cord blood banking, drug discovery, and toxicologytesting. BioLife's cGMP products are serum-free and protein-free, fullydefined, and formulated to reduce preservation-induced, delayed-onset celldamage and death. BioLife's enabling technology provides research andclinical organizations significant improvement in post-preservation cell andtissue viability and function. For more information please visithttp://www.biolifesolutions.com.
This news release contains forward-looking statements as that term isdefined in the Private Securities Litigation Reform Act of 1995. Theseforward-looking statements include any statements that relate to the intent,belief, plans or expectations of the Company or its management, or that arenot a statement of historical fact. Any forward-looking statements in thisnews release are based on current expectations and beliefs and are subject tonumerous risks and uncertainties that could cause actual results to differmaterially. Some of the specific factors that could cause BioLife Solutions'actual results to differ materially are discussed in the Company's recentfilings with the Securities and Exchange Commission. BioLife Solutionsdisclaims any obligation to update any forward-looking statements as a resultof developments occurring after the date of this press release.Media Relations: Investor Relations: Len Hall Matt Clawson Allen & Caron Inc Allen & Caron Inc (949) 474-4300 (949) 474-4300 [email protected] [email protected]
SOURCE BioLife Solutions, Inc.